Translational Control of Lung Cancer
Lung cancer is a leading cause of cancer-related deaths in the U.S. and worldwide. In the US alone, more than 30% of all cancer deaths are caused by lung cancer. Therefore, developing new molecular targets for lung cancer therapy remains a top priority. Non-small cell lung cancer (NSCLC) comprises 80% of all lung cancers. A growing body of evidence clearly indicates that enhanced translation is a characteristic of malignant transformation in a number of tumors, including NSCLC. Even with best-standard medical and surgical therapy, the outlook for patients is often dismal. To this end, these researchers are very interested in the molecular events following translational activation that lead to the development of NSCLC. This will potentially lead to new information regarding tumor growth and therapeutic approaches.